StockNews.com Downgrades Can-Fite BioPharma (NYSE:CANF) to Sell

StockNews.com cut shares of Can-Fite BioPharma (NYSE:CANF) from a hold rating to a sell rating in a report published on Wednesday morning.

Separately, HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Can-Fite BioPharma in a report on Tuesday, November 12th.

Can-Fite BioPharma Trading Down 0.5 %

CANF stock opened at $1.96 on Wednesday. The firm’s 50-day moving average is $2.21 and its two-hundred day moving average is $2.52. The company has a market capitalization of $6.94 million, a price-to-earnings ratio of -1.09 and a beta of 1.39. Can-Fite BioPharma has a 52 week low of $1.87 and a 52 week high of $4.69.

Institutional Trading of Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Armistice Capital LLC boosted its holdings in Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 518,853 shares of the company’s stock after buying an additional 136,055 shares during the quarter. Armistice Capital LLC owned 14.66% of Can-Fite BioPharma worth $1,339,000 as of its most recent SEC filing. 21.00% of the stock is currently owned by institutional investors and hedge funds.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.